Three years of follow-up from the COMISAIR study has found that glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method. Newly published in the journal Diabetes Care, the COMISAIR study, described as a breakthrough since it’s the longest study ever conducted of real-life continuous glucose monitoring (CGM).
The study shows that CGM is superior to self-monitoring blood glucose (SMBG) in increasing a person’s time in range (time when blood glucose is at an ideal level) and reducing time below range, as well as HbA1c levels.
Further, the results show that long-term CGM use supports enduring clinical benefits and reduces likeliness of health complications for people with Type 1 diabetes. These results are timely and relevant, as the diabetes monitoring paradigm will shift to CGM as the standard of care for people with diabetes.
While managing diabetes has historically been full of fingerpricks and unknowns, this study indicates CGM is the most effective tool to help people with diabetes manage their glucose levels and avoid potentially life-threatening highs and lows.
You can download the full study: COMISAIR study followup Sept 2019 (Dexcom CGM).